Featured Content

Latest Press Releases

Jan 10, 2022 Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
Jan 06, 2022 Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
Dec 23, 2021 Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

See All Press Releases

Statements

Our Commitment to Anti-Racism

Named Patient Use Programs

Named Patient Use Program for TEPEZZA® (teprotumumab-trbw)
Named Patient Use Program for UPLIZNA® (inebilizumab-cdon)

Featured Videos

The Horizon Story

The Horizon Story

Deidre Lindsey

Deidre Lindsey

#RAREis: Francis’ Rare Disease Adoption Story in Song

#RAREis: Francis’ Rare Disease Adoption Story in Song

Giving Back is Personal

Giving Back is Personal

Corporate Brochure

Corporate Brochure

Fact Sheets & Downloads

See All Fact Sheets

Logo Download

Download Horizon Logo | RGB Full Color (.jpg)
Download Horizon Logo | RGB Full Color (.png)
Download Horizon Logo | Charcoal Single Color (.jpg)
Download Horizon Logo | Charcoal Single Color (.png)

If you are looking for additional Horizon media assets, please contact corpcomms@horizontherapeutics.com

Media Inquiries

For U.S. media inquiries, contact:
Geoff Curtis
Senior Vice President, Corporate Affairs
media@horizontherapeutics.com
+1 (888) 506-2562

For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373